Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
Related to this article
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL
2
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
3
Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
4
Cutting-Edge Drug Shows Promise for Patients With NRAS-Driven Melanoma
5